Table 1.
Demographic and Questionnaire Data for POTS Participants
| Study Visit Data | All Participants (n = 91) | POTS without hEDS (n = 63) | POTS with hEDS (n = 28) | p-values |
| Age, median (range) | 26 (14–59) | 27(14–59) | 26 (17–40) | 0.944 |
| Sex, female n (%) | 86 (93) | 59 (90) | 27 (96) | 0.257 |
| Beighton Score, | 4 (0–9) | 3 (0–8) | 6 (4–9) | 0.001* |
| median (range) | ||||
| REDCap Questionnaire Data | All Participants (n = 77) | POTS without hEDS (n = 51) | POTS with hEDS (n = 26) | p-values |
| Race, Caucasian (%) | 96% | 94% | 100% | 0.298 |
| Hispanic, (%) | 4% | 6% | 0% | 0.298 |
| Education years, median (range) | 16 (8–22) | 16 (8–22) | 14 (11–20) | 0.959 |
| Age at POTS symptom onset, median years (range) | 16 (5–52) | 15 (5–52) | 18 (10–32) | 0.938 |
| SF-36 Physical Functioning (0–100%), median (IQR) | 40% (25–65) | 40% (25–55) | 38% (24–66) | 0.955 |
| SF-36 Emotional Well Being (0–100%), median (IQR) | 68% (52–80) | 64% (48–80) | 68% (55–81) | 0.754 |
| Orthostatic Grading Scale (0–20), median (IQR) | 13 (9–15) | 13 (13–14) | 14 (8–16) | 0.287 |
| COMPASS 31 Orthostatic Intolerance Score (0–40), median (range) | 24 (20–28) | 24 (20–28) | 28 (24–29) | 0.064 |
| COMPASS 31 Total Score (0–100), median (IQR) | 46 (36–55) | 45 (34–52) | 51 (40–62) | 0.065 |
| Self-reported diagnosis of Ehlers-Danlos Syndromes, n (%) | 35 (46%) | 16 (31%) | 19 (73%) | |
| • Classical | 3 (4%) | 3 (6%) | 0 (0%) | |
| • Hypermobile | 32 (42%) | 13 (25%) | 19 (73%) | |
| • Vascular | 0 (0%) | 0 (0%) | 0 (0%) | |
| • Other | 0 (0%) | 0 (0%) | 0 (0%) | |
| Common Current Medications, n (%) | ||||
| • Beta blockers | 38 (49%) | 28 (55%) | 10 (38%) | 0.040* |
| • Vitamin B12 supplements or injections | 23 (30%) | 15 (29%) | 8 (31%) | 0.961 |
| • Fludrocortisone | 22 (29%) | 16 (31%) | 6 (23%) | 0.274 |
| • Midodrine | 21 (28%) | 13 (25%) | 9 (35%) | 0.383 |
| • Intravenous Saline | 20 (26%) | 12 (24%) | 8 (31%) | 0.571 |
| • Ivabradine | 11 (14%) | 6 (12%) | 5 (19%) | 0.340 |
| • Steroids | 10 (13%) | 6 (12%) | 4 (15%) | 0.710 |
| • Pyridostigmine | 9 (12%) | 5 (10%) | 4 (15%) | 0.450 |
| • Narcotics | 4 (5%) | 2 (4%) | 2 (8%) | 0.396 |
| • Intravenous Immunoglobulin | 4 (5%) | 3 (6%) | 1 (4%) | 0.674 |
Postural orthostatic tachycardia syndrome (POTS), Hypermobile Ehlers-Danlos Syndrome (hEDS), Interquartile range (IQR). Data are shown as median (range or IQR) or percentages. p values represent either Mann-Whitney U nonparametric tests between POTS participants with versus without hEDS, or chi-square analysis for proportions of POTS participants with versus without hEDS that were female or currently taking common medications.
*
represents p value < 0.05.